Inversago Pharma

It's all
about life™

Pioneering the
comeback of CB1
inverse agonists

About Inversago Pharma

Inversago Pharma develops new generations of peripherally-restricted cannabinoid-1 receptor (CB1) inverse agonists/ antagonists for the treatment of Prader-Willi Syndrome (PWS), Type-1 Diabetes (T1D), obesity and other metabolic disorders such as non-alcoholic steatohepatitis (NASH). Inversago’s technology addresses limits associated with first generation CB1 blockers, allowing the company to exploit their full medical potential.

Discover our company

Targeting unmet needs for a better living

Inversago believes it has the technology to resolve a decade-old problem related to a clinically-validated, in-depth studied, therapeutic approach: safe and efficient CB1 receptor blockade to address a broad range of medical indications (obesity-related conditions, diabetes, NASH/NAFLD, as well as fibrotic disorders).

Our development plan paves the way for a new generation of CB1 inverse agonists/antagonists, in order to strengthen the endocannabinoid system’s ability to regulate the human body’s homeostasis in a more effficient manner.

Learn More

Indications

The peripheral endocannabinoid system is believed to contribute to homeostasis by controlling appetite, food intake and energy balance. Any medical condition disrupting homeostasis, such as obesity, type 2 diabetes or various genetic conditions, is called a metabolic disorder.

In order to address these indications, Inversago focuses its research on the peripheral endocannabinoid system, more precisely the CB1 receptor activity, whose regulation is recognized to be involved in many conditions.